Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy

Josefina Marin
María Laura Acosta Felquer
Enrique R Soriano

Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Abstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of ankylosing spondylitis (AS) in the USA and for AS and non-radiographic axial spondyloarthritis (nr-axSpA) in Europe and in some Latin American countries. CZP lacks Fc region, preventing complement fixation and cytotoxicity mediated by antibody; CZP does not actively cross the placenta, unlike other TNFi. RAPID-axSpA study is a Phase III trial conducted in patients with AS and nr-axSpA as double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Of a total of 325 patients recruited, 107 patients were assigned to placebo and 218 patients to CZP (111 to CZP 200 mg Q2W, 107 to CZP 400 mg Q4W). Improvements in axial involvement, joint involvement, enthesitis and quality of life were reported in patients treated with CZP. Safety profile was like that reported for other TNFi in axSpA patients. In this article, we summarized the pharmacology and we reviewed the efficacy and tolerability of this drug for the treatment of axSpA. Some special considerations of CZP during pregnancy are included. CZP, the latest TNFi to be approved, showed efficacy in all manifestations of AS and nr-axSpA.

Keywords: certolizumab pegol, tumor necrosis factor-α inhibitors, ankylosing spondylitis, non-radiographic axial spondyloarthritis, efficacy, safety

Introduction

Axial spondyloarthritis (axSpA) is a chronic disease, characterized by involvement of the sacroiliac (SI) joints and spine, resulting in chronic inflammatory back pain.

The estimated prevalence of axSpA is between 0.2% and 1.2% in white European populations.1 The diagnosis is often delayed by up to 8 years, mainly because sacroiliitis, which is considered a hallmark of ankylosing spondylitis (AS), is not visible on plain radiographs in the early stages of the disease.2,3

For the diagnosis of AS, fulfillment of modified New York classification criteria, which requires the presence of radiographic sacroiliitis, is needed.4 With the use of magnetic resonance imaging (MRI) allowing earlier detection of inflammation in the SI joints, it has been possible to identify patients with clinical characteristics of AS, but who do not fulfill the modified New York criteria. These patients have been classified as having non-radiographic axSpA (nr-axSpA).5,6 New classification criteria5-7 were developed in an attempt to improve diagnostic delay.8,9 This new criteria allowed the inclusion of nr-axSpA in clinical studies.

It has been proposed that nr-axSpA may represent an early form of AS, as many patients progress to AS over time.10,11 The fact that not all patients progress to AS over...
time, and the identification of genetic and sex differences between AS and nr-axSpA, has led some to think that they might be distinct diseases\textsuperscript{12–14} and have led to the reluctance of FDA to approve tumor necrosis factor inhibitors (TNFis) in nr-axSpA.\textsuperscript{15} In general, disease activity and burden of symptoms did not differ between both, and both need the same kind of treatment.\textsuperscript{16–19}

The treatment of SpA has changed drastically since the use of biological agents such as TNFi.\textsuperscript{20–23} Certolizumab pegol (CZP), a novel TNFi, was the last TNFi approved for the treatment of axSpA (European Commission [EMA] and AS (EMA (CZP), a novel TNFi, was the last TNFi approved for the treatment of axSpA (European Commission [EMA] and AS (EMA and FDA). We will describe the current evidence for the use of CZP in the treatment of active axSpA in the following text.

Certolizumab pegol

CZP is formed by the combination of a humanized Fab fragment (50 kDa) and a 40-kDa polyethylene glycol moiety (a polymer that is not immunogenic or toxic).\textsuperscript{24,25} Its molecular structure leads to an increase of plasma half-life of the molecule to about 2 weeks. This allows 2–4 weekly subcutaneous injections. PEGylation is also assumed to be associated with decreased immunogenicity.\textsuperscript{25} The lack of Fc region prevents complement fixation and cytotoxicity mediated by antibody. CZP does not lead to apoptosis of peripheral blood monocytes or lymphocytes or neutrophil necrosis.\textsuperscript{24,25}

CZP has been characterized as producing dose-dependent inhibition of TNF (soluble and membrane-bounded TNF) and inhibition of the production of lipopolysaccharide-induced TNF-\(\alpha\) and IL-1\(\beta\) by monocytes. CZP does not induce complement or cytotoxicity mediated by antibody in vitro and induces cell death by a nonapoptotic signaling (probable by transmembrane TNF-\(\alpha\)). It has also been shown greater drug distribution into inflamed tissues than that of infliximab (IFX) and adalimumab (ADA).\textsuperscript{24,26}

Clinical efficacy

CZP has been evaluated in randomized controlled trials: RAPID-axSpA trials.\textsuperscript{27–32} The objective of RAPID-axSpA (NCT01087762), a 4-year, Phase III randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204, was to study the efficacy and safety of CZP for the treatment of axSpA.\textsuperscript{27–32}

Patients were recruited from 83 different sites in central/Eastern and Western Europe, North America and Latin America. To be included in the study, patients need to fulfill Assessment of SpondyloArthritis international Society (ASAS) criteria for the diagnosis of SpA and to have active disease, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \(\geq\) 4 and spinal pain \(\geq\) 4 on a 0–10 Numerical Rating Scale. Intolerance or inadequate response to at least one nonsteroidal anti-inflammatory drug (NSAID) was also needed.\textsuperscript{27} A total of 325 patients were recruited. One hundred and seven patients were assigned to placebo and 218 patients to CZP (111 to CZP 200 mg Q2W and 107 to CZP 400 mg Q4W). Of the group of patients treated with CZP, 121 had AS and 97 had nr-axSpA (Figure 1).\textsuperscript{28} Baseline disease activity among the groups of patients and between AS and nr-axSpA patients was similar. More than half of the patients in the CZP-treated group (63\% [199/315]) completed the study at week 204. The completion rates were similar between both CZP groups and between AS and nr-axSpA patients. ASAS20, ASAS40, BASDAI, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Metrology Index and Bath Ankylosing Spondylitis Functional Index responses (nonresponder imputation and observed case) at week 204 are shown in Table 1.\textsuperscript{31,32}

Ankylosing Spondylitis Disease Activity Score-1D sustained remission, and ASAS partial remission was achieved by one-third of patients with similar responses rates among AS and nr-axSpA (Table 1).\textsuperscript{27,32}

Patient-reported outcomes

Patients-reported outcomes (PROs) are widely used measurements that allow the collection of information related to specific disease aspects, usually not scored by the physicians, directly from the patient. Among them, improvements in back pain, fatigue, sleep (Medical Outcomes Study Sleep Scale), SF-36 (both physical and mental outcomes) and Ankylosing Spondylitis Quality of Live were seen after 24 weeks of the initiation of treatment with CZP, and these results were maintained until week 204\textsuperscript{28,31} (Table 2). Comparable improvement in total back pain, fatigue and Ankylosing Spondylitis Quality of Life was seen in AS and nr-axSpA groups.\textsuperscript{28} Clinically relevant improvement in pain response to CZP was observed as rapid as from day 2.\textsuperscript{30}

Peripheral arthritis and enthesitis

By week 24, similar improvements in arthritis and enthesitis were seen in both AS and nr-axSpA patients,\textsuperscript{28} which was maintained until week 204 (Table 3).\textsuperscript{27} Enthesitis was assessed by the MASES score. Both AS and nr-axSpA patients had a similar improvement in mean MASES score, although baseline scores were higher in nr-axSpA patients (AS: 4.7 and nr-axSpA: 5.6).\textsuperscript{28}
MRIs of the sacroiliac (SI) joints and spine were performed at baseline and week 12, 48 and 96. For lesions on MRI in the SI joints, the Spondyloarthritis Research Consortium of Canada (SPARC) scoring method was used, and for lesions in the spine, the Berlin modification of Ankylosing Spondylitis spine MRI scoring system for disease activity (Berlin) was used. Only patients with MRI evidence of inflammation at baseline were analyzed for MRI remission.

CZP treatment of patients with axSpA significantly reduced MRI inflammation in the SI joints and spine over 12 weeks. Improvements were seen and maintained through week 96 for AS and nr-axSpA patients treated with CZP.

Nonradiographic axial spondyloarthritis
RAPID-axSpA is the only trial including patients with both r-axSpA and nr-axSpA with either positive C-reactive protein (CRP) or MRI for lesions on MRI in the spine (the Berlin modification of Ankylosing Spondylitis spine MRI scoring system for disease activity (Berlin) was used). Only patients with MRI evidence of inflammation at baseline were analyzed for MRI remission.

Safety
The safety profile of these TNFi has been shown in different clinical trials performed in patients with psoriatic and rheumatoid arthritis. The initial RAPID axSpA trial reported that the adverse events (AEs) were mild to moderate in both CZP and placebo groups. During the 24 weeks of the study, any AE occurred in 62.6% of the placebo group and 76% of the CZP group. Serious AEs occurred in 4.7% and 3.6% in the first group and second group, respectively, and serious infections occurred in 0% and 1.8% in the first group and second group, respectively. In the placebo group, any AE, serious AEs, and serious infections occurred in 74.8%, 6.5%, and 0%, respectively. No deaths, malignancies or tuberculosis events were observed, and no new safety signals for CZP in AS were observed compared to other indications for CZP.
Table 1: Efficacy of subcutaneous certolizumab pegol in adult patients with axial spondyloarthritis in the randomized, double-blind, multicenter RAPID-axSpA trial.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>All patients axSpA (N = 218)</th>
<th>AS (N = 121)</th>
<th>nr-axSpA (N = 97)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 24</td>
<td>Week 24</td>
</tr>
<tr>
<td>N = 218</td>
<td>OC (N = 205)</td>
<td>Imputed</td>
<td>OC (N = 140)</td>
</tr>
<tr>
<td>ASDAS-ID, n/N (%)</td>
<td>66/205 (32.2)</td>
<td>66 (30.3)</td>
<td>44/140 (31.4)</td>
</tr>
<tr>
<td>ASDAS-MD, n/N (%)</td>
<td>3 (1.4)</td>
<td>51/205 (24.9)</td>
<td>54 (24.8)</td>
</tr>
<tr>
<td>ASAS20, n/N (%)</td>
<td>147/201 (73.1)</td>
<td>149 (68.3)</td>
<td>113/135 (83.7)</td>
</tr>
<tr>
<td>ASAS40, n/N (%)</td>
<td>111/201 (55.2)</td>
<td>113 (51.8)</td>
<td>91/135 (68.1)</td>
</tr>
<tr>
<td>ASAS S/6, n/N (%)</td>
<td>90/199 (45.2)</td>
<td>92 (42.2)</td>
<td>72/134 (53.7)</td>
</tr>
<tr>
<td>ASAS-PR, n/N (%)</td>
<td>66/204 (32.4)</td>
<td>66 (30.3)</td>
<td>50/137 (36.5)</td>
</tr>
<tr>
<td>BASDAI ≤2, n/N (%)</td>
<td>66/205 (32.2)</td>
<td>66 (30.3)</td>
<td>46/142 (32.4)</td>
</tr>
<tr>
<td>BasDAI 50, n/N (%)</td>
<td>114/205 (55.6)</td>
<td>114 (52.3)</td>
<td>89/140 (63.6)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>3.8 (0.9)</td>
<td>2 (1)</td>
<td>1.9 (0.9)</td>
</tr>
<tr>
<td>ASDAS</td>
<td>Mean (SD)</td>
<td>6.4 (1.5)</td>
<td>6.3 (2.2)</td>
</tr>
<tr>
<td>BASDAI</td>
<td>Mean (SD)</td>
<td>5.3 (2.3)</td>
<td>3 (2.5)</td>
</tr>
<tr>
<td>BASRI</td>
<td>Mean (SD)</td>
<td>3.8 (1.7)</td>
<td>3.2 (1.7)</td>
</tr>
</tbody>
</table>

Abbreviations: axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial SpA; OC, observed cases; n/N, number positive/number included; ASAS, Assessment of SpondyloArthritis international Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASAS-PR, Assessment of SpondyloArthritis international Society Partial Remission criteria; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index.
Table 2 Effect of subcutaneous certolizumab pegol on key patient-reported outcomes in the RAPID-axSpA study²⁰

<table>
<thead>
<tr>
<th>Patient-reported outcome</th>
<th>All patients (N = 218)</th>
<th>AS (N = 121)</th>
<th>nr-axSpA (N = 97)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 24</td>
<td>Week 204</td>
</tr>
<tr>
<td></td>
<td>N = 218</td>
<td>N = 205</td>
<td>Imputed OC (N = 140)</td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>6.6 (1.9)</td>
<td>2.9 (2.4)</td>
<td>3 (2.5)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>6.8 (1.8)</td>
<td>3.9 (2.6)</td>
<td>4.1 (2.7)</td>
</tr>
<tr>
<td>Sleep</td>
<td>49 (19.2)</td>
<td>35.3 (20.1)</td>
<td>36.2 (20.2)</td>
</tr>
<tr>
<td>Nocturnal back pain</td>
<td>6.9 (2.3)</td>
<td>3.1 (2.6)</td>
<td>3.3 (2.7)</td>
</tr>
<tr>
<td>Total back pain</td>
<td>7 (2.3)</td>
<td>3.5 (2.6)</td>
<td>3.8 (2.7)</td>
</tr>
<tr>
<td>ASQoL</td>
<td>11.6 (4.4)</td>
<td>6.2 (5.5)</td>
<td>6.5 (5.6)</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>32.4 (7.5)</td>
<td>42.1 (10)</td>
<td>41.8 (9.9)</td>
</tr>
<tr>
<td>SF-36 MCS</td>
<td>41 (12)</td>
<td>46.6 (11.6)</td>
<td>46 (11.8)</td>
</tr>
</tbody>
</table>

Note: Values are given as mean and (SD), unless stated otherwise.
Abbreviations: axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial SpA; OC, observed cases; SF-36 PCS, Short Form (36) Health Survey Physical Component Summary; SF-36 MCS, Short Form (36) Health Survey Mental Component Summary.
### Table 3 Effect of subcutaneous certolizumab pegol on peripheral arthritis and enthesitis in the RAPID-axSpA study

<table>
<thead>
<tr>
<th>Articular manifestations, mean (SD)</th>
<th>All patients axSpA (N = 218)</th>
<th>AS (N = 121)</th>
<th>nr-axSpA (N = 97)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 24</td>
<td>Week 24</td>
</tr>
<tr>
<td></td>
<td>OC</td>
<td>LOCF</td>
<td>OC</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N = 76</td>
<td>76</td>
<td>Mean 4.2</td>
<td>72</td>
</tr>
<tr>
<td>SD 5.6</td>
<td></td>
<td>SD 2.7</td>
<td></td>
</tr>
<tr>
<td>N = 89</td>
<td></td>
<td></td>
<td>N = 89</td>
</tr>
<tr>
<td>SD 5.5</td>
<td></td>
<td>SD 6.5</td>
<td></td>
</tr>
<tr>
<td>N = 148</td>
<td>Mean 5.1</td>
<td></td>
<td>Mean 2.3</td>
</tr>
<tr>
<td>SD 3.5</td>
<td></td>
<td></td>
<td>SD 3.5</td>
</tr>
<tr>
<td>Complete resolution of enthesitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MASES = 0, n/N (%)</td>
<td>0</td>
<td>74/141</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>(52.5)</td>
<td>(50.7)</td>
<td>(63.5)</td>
</tr>
<tr>
<td>Heel enthesitis complete resolution, n/N(%)</td>
<td>0</td>
<td>32/49</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>(65.3)</td>
<td>(61.5)</td>
<td>(74.3)</td>
</tr>
</tbody>
</table>

**Abbreviations:** axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial SpA; OC, observed cases; LOCF, last observation carried forward.

### Pregnancy

Drugs used to treat women at fertile age, commonly affected with rheumatic diseases, may alter fertility and increase the risk of congenital anomalies. In a study of 315 AS patients in the RAPID-axSpA trial over 96 weeks, 74% (88.6%) of patients were male, and 26% (11.4%) were female. Most of these side effects were mild (74.9%), moderate (11.4%), and severe (4.6%).

### Drug survival

Drug survival is a surrogate of efficacy and safety in observational studies. Recently, results from a two-center cohort of United Kingdom have been published. Median survival duration for first TNFi was 10.2 years. Most of these side effects were mild (74.9%), moderate (11.4%), and severe (4.6%).

### Pregnancy

The increased risk of serious infections in pregnant women has been well documented. They reported serious AEs in 41 patients (13.0%), which were predominantly infections and infestations (3.8%). There were no fatalities, malignancies, or drug-related deaths. A meta-analysis of six RCTs showed that the rate of serious infections in pregnant women was 9.3% (95% CI: 3.3–15.4) compared to 6.1% (95% CI: 5.0–7.2) in non-pregnant women.

### Safety

The most common side effects observed in the study were infections (3.7%), gastrointestinal disorders (3.6%), and dermatological disorders (3.6%). There were no fatalities, malignancies, or drug-related deaths. A meta-analysis of six RCTs showed that the rate of serious infections in pregnant women was 9.3% (95% CI: 3.3–15.4) compared to 6.1% (95% CI: 5.0–7.2) in non-pregnant women.
risk of miscarriages and congenital abnormalities. On the other side, disease activity could be an independent risk factor for adverse pregnancy outcomes.46–48

Concerns related to the safety of biologics during pregnancy existed until few years ago when data from many studies suggested that pregnant women with inflammatory bowel disease or inflammatory arthritis receiving TNF inhibitors was not associated with adverse pregnancy outcomes or any increase in teratogenicity.49–53

CZP differs from other TNF blockers in that it has no Fc region and is not actively transported through the placenta, and as expected, concentrations in the fetus would be lower.54

In a study performed in 2013, authors measured the serum and cord concentrations of drugs in the mother, infant and cord blood.55 They included 31 pregnant women with inflammatory bowel disease receiving IFX (n=11), ADA (n=10) and CZP (n=10). Drug concentrations in infants at birth and cord were compared with those of the mother. IFX and ADA concentrations were higher in infants at birth and their cords than in their mothers. The median level of IFX and ADA in the cord was 160% and 153% higher than that of the mother, respectively. By contrast, the median level of CZP in the cord was 3.9% higher than that of the mother. They detected IFX and ADA in the infants for as long as 6 months, while CZP in the infant plasma and cord was undetectable. No congenital malformations or adverse pregnancy outcomes were reported.24,55

An analysis of 253 pregnancies with known outcomes from a total of 625 pregnancies from UCB Pharma global safety database was published.56 Only one-third of pregnancies continued the treatment through second or third trimester, while most of women were exposed during the first trimester. Most of the women had Crohn's disease. In total, 75.5% pregnancies resulted in live births. Ten percent of women had elective terminations, and spontaneous miscarriages were reported in 14% of patients.56 Three congenital malformations were reported after maternal exposure, which is comparable to that of the general population.56

The 2016 “EULAR recommendations for use of antirheumatic drugs during pregnancy and lactation” recommended discontinuing monoclonal antibodies IFX, ADA and golimumab around gestational week 20. Etanercept (a fusion protein) may be continued until week 30–32, and CZP has minimal transplacental passage for use throughout pregnancy but needs confirmation from prospective studies.51

Administration and doses

In the United States, CZP has been approved by FDA only for the treatment of adult patients with active AS.42

In the EU, subcutaneous CZP has been approved for the treatment of patients with severe active AS who have had an inadequate response to or are intolerant to NSAIDs and adults with severe active axSpA without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI who have had an inadequate response to or are intolerant to NSAIDs.53

The recommended doses and administration schedules are 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at weeks 2 and 4, followed by 200 mg every other week or 400 mg every 4 weeks.

The purpose of indicating LD is to achieve high concentrations of the drug during early stages of treatment, which accelerates drug response and reduces the production of drug antibodies.24

Place in therapy

TNFis are recommended in all international and local guidelines after NSAID failure in AS and nr-axSpA.7,58 CZP, a new TNFi, is placed at that same level, although some concerns due to less long-term and real-life date might be raised. CZP demonstrated efficacy not only in axial involvement but also in peripheral arthritis and enthesitis and hence should be considered in patients with more than one involvement. Because of its advantages related to low cross-placental and breast milk transfer, CZP may be considered as the TNFi of choice in female patients considering pregnancy and of course in pregnant patients. As always, risks and benefits of therapy should be discussed with the patient taking into account neonatal risks and the risk of disease flare. Also, the course of a pregnancy with a very active disease might have far more consequences to neonatal development. In general, it is not recommended to switch to CZP if a pregnant patient is doing well on other TNFi. Having other options for the treatment of these patients, is there any advantage to use CZP? Some CZP features, apart from placental and breast milk transfer, that make CZP in some way different to other TNFi might be considered at the time of offering the patient a new treatment: a fortnightly or monthly subcutaneous drug regime due to a long half-life; quick and long-lasting efficacy and low generation of anti-TNFi (anti-ADA) antibodies after a loading dose; and proven good distribution into inflamed tissues due to PEGylation. On the other hand, up to now, in spite of these differences, CZP safety profile looks similar to other TNFi.

Conclusion

CZP, the newest original TNFi, has shown very good efficacy and has sustained on the long term in several manifestations of axSpA, including peripheral disease, enthesitis and PROs.
CZP is a new TNFi with a novel composition that is gaining experience around the world and performing according to expectations.

Disclosure
ERS participated in advisory boards, gave conferences or received grants from Abbvie, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz and UCB. MLAF and JM gave conferences for Novartis. The authors report no other conflicts of interest in this work.

References


Open Access Rheumatology: Research and Reviews Publish your work in this journal

Open Access Rheumatology: Research and Reviews is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of clinical and experimental rheumatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of rheumatological diseases; Investigation, treatment and management of rheumatological diseases; Clinical trials and novel pharmacological approaches for the treatment of rheumatological disorders. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.